Genocea presents data demonstrating potential of ATLAS platform
Genocea Biosciences presented clinical and preclinical data demonstrating the potential of Genocea's unique, biology-driven ATLAS platform to select neoantigens for inclusion in anti-tumor immunotherapies. The company said, "Striking clinical evidence shows that the presence of inhibitory neoantigens in an otherwise protective therapeutic vaccine completely suppressed anti-tumor immune responses and promoted tumor growth in pre-clinical models." These data were presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer. "These results point to the true power and utility of ATLAS," said Jessica Baker Flechtner, Chief Scientific Officer of Genocea. "Our findings confirm that responses to inhibitory neoantigens can undermine a cancer immunotherapy, even if it also contains stimulatory neoantigens. ATLAS is the only technology able to identify these inhibitory peptides, offering further proof of its potential to identify the targets that matter most."